Document is current
Any future updates will be listed below
-
Authors
Haue, Amalie D. https://orcid.org/0000-0001-7656-7976
Holm, Peter C.
Banasik, Karina https://orcid.org/0000-0003-2489-2499
Aunstrup, Kenny Emil
Johansen, Christian Holm https://orcid.org/0000-0001-8665-2111
Lundgaard, Agnete T. https://orcid.org/0000-0001-7447-6560
Muse, Victorine P.
Röder, Timo
Westergaard, David https://orcid.org/0000-0003-0128-8432
Chmura, Piotr J. https://orcid.org/0000-0002-9371-6918
Christensen, Alex H.
Weeke, Peter E.
Sørensen, Erik https://orcid.org/0000-0002-5002-9077
Pedersen, Ole B. V. https://orcid.org/0000-0003-2312-5976
Ostrowski, Sisse R. https://orcid.org/0000-0001-5288-3851
Iversen, Kasper K.
Køber, Lars V. https://orcid.org/0000-0002-6635-1466
Ullum, Henrik
Bundgaard, Henning https://orcid.org/0000-0002-0563-7049
Brunak, Søren https://orcid.org/0000-0003-0316-5866
-
Funding
Funding for this research was provided by:
Novo Nordisk Fonden (NNF17OC0027594, NNF14CC0001)
NordForsk (5184-00102B)
- License Information
-
More Information
Article History
Received: 22 August 2024
Accepted: 30 July 2025
First Online: 26 August 2025
Competing interests
: S.B. received personal compensation for managing board membership at Intomics and Proscion and is a scientific advisory board member of Biocenter Finland, Health Data Research UK, the Finnish Center of Excellence in Complex Disease Genetics, ELIXIR Node (Luxembourg), Lund University Diabetes Centre (Lund, Sweden), and SciLifeLab (Stockholm, Sweden). S.B. reports stocks in Intomics, Hoba Therapeutics Aps, Novo Nordisk, Elly Lilli & Co., and Lundbeck. H.B. has received lecture fees from Amgen and Bristol-Myers Squibb. L.K. is a member of the speaker steering committee for AstraZeneca and Novartis. L.K. has received lecture fees from Novo Nordisk and Boehringer Ingelheim. The remaining authors declare no competing interests.
